GlassScriptPhysician profile
David Paikal
NPI 1578659405
$5,810.10
in general payments reported to CMS, 2019-2025
27 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $305 · 2021: $286 · 2022: $603 · 2023: $887 · 2024: $1,174 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,143.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,001.46 | 2019 | |
| Alcon Vision LLC | $748.84 | 2019-2025 | Hydrus Microstent, Voyager Dslt, Tryptyr |
| Lumenis Be INC | $478.89 | 2023-2024 | M22, Optilight |
| Glaukos Corporation | $455.06 | 2024-2025 | Idosetr, Idose, Radius |
| Oyster Point Pharma, INC. | $408.21 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $374.23 | 2022-2025 | Miebo, Vyzulta, Lotemax Sm |
| Novartis Pharmaceuticals Corporation | $364.90 | 2019-2023 | |
| Allergan, INC. | $308.89 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $296.06 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $264.74 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $263.76 | 2021-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.49 | 2019-2021 | |
| Harrow Eye, LLC | $101.86 | 2024-2025 | Vevye |
| Optos, INC. | $91.46 | 2019-2021 | |
| Abbvie INC. | $72.53 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $62.32 | 2022-2023 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $61.99 | 2019-2020 | |
| Amgen INC. | $57.01 | 2025 | Tepezza |
| Shire North American Group INC | $47.16 | 2019 | |
| Ocular Therapeutix, INC. | $42.56 | 2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $41.12 | 2019-2022 | |
| Alimera Sciences, INC. | $39.02 | 2019 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Abiomed | $26.67 | 2022 | |
| Biotissue Holdings INC. | $19.57 | 2023 | |
| New World Medical,INC. | $19.26 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Paikal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.